G1 Therapeutics (G1 Therapeutics) FCF Yield % : -6.98 (As of May. 10, 2024)

View and export this data going back to 2017. Start your Free Trial

What is G1 Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, G1 Therapeutics's Trailing 12-Month Free Cash Flow is $-18.18 Mil, and Market Cap is $249.38 Mil. Therefore, G1 Therapeutics's FCF Yield % for today is -6.98%.

The historical rank and industry rank for G1 Therapeutics's FCF Yield % or its related term are showing as below:

GTHX' s FCF Yield % Range Over the Past 10 Years
Min: -108.07 Med: -27.2 Max: -6.98
Current: -6.98

During the past 9 years, the highest FCF Yield % of G1 Therapeutics was -6.98%. The lowest was -108.07%. And the median was -27.20%.

GTHX's FCF Yield % is ranked better than
64.33% of 1556 companies
in the Biotechnology industry
Industry Median: -14.085 vs GTHX: -6.98

G1 Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was -61.47%.

G1 Therapeutics FCF Yield % Historical Data

The historical data trend for G1 Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G1 Therapeutics FCF Yield % Chart

G1 Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-10.29

-12.21

-30.40

-46.18

-24.21

G1 Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial															-83.94	43.76	-56.71	-32.31	-15.77

Competitive Comparison of G1 Therapeutics's FCF Yield %

For the Biotechnology subindustry, G1 Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

G1 Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, G1 Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where G1 Therapeutics's FCF Yield % falls into.

G1 Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

G1 Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-38.337	/	158.374605
	=	-24.21%

G1 Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-8.898	*	4	/	225.652608
	=	-15.77%

G1 Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

G1 Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of G1 Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

G1 Therapeutics (G1 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G1 Therapeutics Inc (NAS:GTHX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

G1H:Germany

Address

700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709

Website

https://www.g1therapeutics.com

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat the types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.

Executives

John V. Umstead	officer: Chief Financial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Rajesh Malik	officer: Chief Medical Officer	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Mark Avagliano	officer: Chief Business Officer	79 T.W. ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Terry L Murdock	officer: Chief Operating Officer
Bailey John E. (jack) Jr.	director, officer: President and CEO	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Andrew Perry	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Mark A. Velleca	director, officer: President and CEO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Monica R. Thomas	officer: General Counsel	700 PARK OFFICES, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Jennifer K. Moses	officer: CFO	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
James S. Hanson	officer: General Counsel	79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Norman Sharpless	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 22709
Jacks Lee	director	700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709
Seth Rudnick	director	7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS, MISSISSAUGA A6 L5N 0E4
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421
Soma Gupta	officer: Chief Commercial Officer	C/O G1 THERAPEUTICS, INC., 700 PARK OFFICES DRIVE, SUITE 200, RESEARCH TRIANGLE PARK NC 27709